How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,918 results for

Myoclonus

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab (PubMed)

Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab 26788132 2016 01 20 2018 11 13 1756-2856 9 1 2016 Jan Therapeutic advances in neurological disorders Ther Adv Neurol Disord Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. 69-73 10.1177/1756285615614812 Magira Eleni E EE First

Full Text available with Trip Pro

2016 Therapeutic advances in neurological disorders

122. Reversible myoclonus, asterixis, and tremor associated with high dose trimethoprim-sulfamethoxazole: a case report (PubMed)

Reversible myoclonus, asterixis, and tremor associated with high dose trimethoprim-sulfamethoxazole: a case report Reversible myoclonus, tremor, and asterixis induced by high dose trimethoprim-sulfamethoxazole.The patient was a 66-year-old male with T9 AIS(1) C quadriplegia secondary to spinal cord compression by a tumor due to large B cell lymphoma. Subsequent to tumor resection and chemotherapy, the patient was discovered to have Pneumocystis jiroveci pneumonia (PJP). Once started on high (...) to be the first reported case of reversible myoclonus, tremor, and asterixis induced by high dose TMP-SMX in the spinal cord injury population. Early recognition of TMP-SMX induced complications were of key importance as they negatively impacted the rehabilitation process. We also recommend consideration of symptomatic treatment with levetiracetam for the duration of required TMP-SMX therapy as it appeared to mitigate the severity of our patient's movement disorders.

Full Text available with Trip Pro

2016 The journal of spinal cord medicine

123. Speech-activated Myoclonus Mimicking Stuttering in a Patient with Myoclonus–Dystonia Syndrome (PubMed)

Speech-activated Myoclonus Mimicking Stuttering in a Patient with Myoclonus–Dystonia Syndrome Acquired neurogenic stuttering has been considered a fairly uncommon clinical occurrence; speech-activated myoclonus is a rare entity that can mimic stuttering and is caused by a wide array of etiologies.Here we report a patient with myoclonus-dystonia syndrome (MDS), due to an identified disease-causing mutation, who displayed speech-activated myoclonus mimicking stuttering.In MDS, myoclonus has (...) only infrequently been reported to affect speech. This case further expands the spectrum of conditions causing the rare clinical phenomenon of speech-activated myoclonus.

Full Text available with Trip Pro

2016 Tremor and Other Hyperkinetic Movements

124. Progressive myoclonus epilepsy associated with SACS gene mutations (PubMed)

Progressive myoclonus epilepsy associated with SACS gene mutations Pathogenic variants in the SACS gene (OMIM #604490) cause autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). ARSACS is a neurodegenerative early-onset progressive disorder, originally described in French Canadians, but later observed elsewhere.(1) Whole-exome sequencing of a large group of patients with unclassified progressive myoclonus epilepsies (PMEs) identified 2 patients bearing SACS gene mutations.(2) We

Full Text available with Trip Pro

2016 Neurology: Genetics

125. Giant early components of somatosensory evoked potentials to tibial nerve stimulation in cortical myoclonus (PubMed)

Giant early components of somatosensory evoked potentials to tibial nerve stimulation in cortical myoclonus Enlarged cortical components of somatosensory evoked potentials (giant SEPs) recorded by electroencephalography (EEG) and abnormal somatosensory evoked magnetic fields (SEFs) recorded by magnetoencephalography (MEG) are observed in the majority of patients with cortical myoclonus (CM). Studies on simultaneous recordings of SEPs and SEFs showed that generator mechanism of giant SEPs

Full Text available with Trip Pro

2016 NeuroImage : Clinical

126. Ataxia, dystonia and myoclonus in adult patients with Niemann-Pick type C (PubMed)

Ataxia, dystonia and myoclonus in adult patients with Niemann-Pick type C Niemann-Pick type C (NP-C) is a rare autosomal recessive progressive neurodegenerative disorder caused by mutations in the NP-C 1 or 2 gene. Besides visceral symptoms, presentation in adolescent and adult onset variants is often with neurological symptoms. The most frequently reported presenting symptoms of NP-C in adulthood are psychiatric symptoms (38 %), cognitive decline (23 %) and ataxia (20 %). Myoclonus can (...) was evaluated by questionnaires (Rand-36, SIP-68, HAQ). In four of the five patients with myoclonic jerks simultaneous EEG with EMG was performed.A movement disorder was the initial neurological symptom in six patients: three with myoclonus and three with ataxia. Two others presented with psychosis. Four experienced cognitive deficits early in the course of the disease. Patients showed cognitive deficits in all investigated domains. Five patients showed myoclonic jerks, including negative myoclonus. In all

Full Text available with Trip Pro

2016 Orphanet journal of rare diseases

127. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. (PubMed)

A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. To evaluate the efficacy and safety of zonisamide in patients with myoclonus-dystonia.We conducted a randomized, double-blind, placebo-controlled crossover trial of zonisamide (300 mg/d) in 24 patients with myoclonus-dystonia. Each treatment period consisted of a 6-week titration phase followed by a 3-week fixed-dose phase. The periods were separated by a 5-week washout period. The co-primary outcomes (...) were action myoclonus severity (section 4 of the Unified Myoclonus Rating Scale [UMRS 4]) and myoclonus-related functional disability (UMRS 5). Secondary outcomes included dystonia severity, assessed with the movement and disability subscales of the Burke-Fahn-Marsden-Dystonia Rating Scale (BFM), the Clinical Global Impression-Improvement scale (CGI), and safety measures. Wilcoxon signed-rank tests for paired data were used to analyze treatment effects.Twenty-three patients (11 men, 12 women) were

2016 Neurology

128. Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) - Full Text (...) View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome

2013 Clinical Trials

129. Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine (PubMed)

Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine A 76-year-old man was admitted to hospital with a right-sided fractured neck of femur requiring repair via a cemented hemiarthroplasty. Intraoperatively he received 10 mg of intravenous morphine. Post-operatively he received a short course of low-dose oral opioids and subsequently developed myoclonic jerks and hyperalgesia. The opioids were discontinued and both adverse effects resolved. This case (...) report discusses the concurrent development of myoclonus and hyperalgesia following a low dose of opioids and explores possible management options.

Full Text available with Trip Pro

2016 British journal of pain

130. Therapeutic Developments for Tics and Myoclonus. (PubMed)

Therapeutic Developments for Tics and Myoclonus. Tics and myoclonus are phenomenologically similar given that both are jerk-like movements, but, in contrast to myoclonus, tics are often preceded by premonitory sensations and are typically associated with a variety of behavioral comorbidities, including attention deficit and obsessive-compulsive disorder. There are many other clinical features that help differentiate these two hyperkinetic disorders. Whereas behavioral and antidopaminergic (...) therapies are most effective in the management of tics, clonazepam, other anticonvulsants, and serotonergic drugs are often used to control myoclonic movements. Botulinum toxin may also be helpful in focal tics and in segmental forms of myoclonus. DBS plays an increasingly important role in the treatment of these disorders, particularly when they are generalized and are disabling despite optimal medical therapy.© 2015 International Parkinson and Movement Disorder Society.

2015 Movement Disorders

131. Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus

Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02518789 Recruitment Status : Unknown Verified August 2015 by Tang-Du Hospital. Recruitment status was: Not yet recruiting First Posted : August

2015 Clinical Trials

132. Primary pancreatic neuroblastoma presenting with opsoclonus–myoclonus syndrome (PubMed)

Primary pancreatic neuroblastoma presenting with opsoclonus–myoclonus syndrome Although neuroblastoma is a common solid organ malignancy in children, primary pancreatic neuroblastoma is a rare entity in children, with very few cases reported in the literature. The case discusses the presentation of a 21-month-old female presenting to the neurology clinic with ataxia and erratic eye movements. Our case illustrates the computed tomography, ultrasound, and scintigraphic findings of primary (...) pancreatic neuroblastoma presenting as opsoclonus-myoclonus syndrome. Computed tomography and ultrasound demonstrated a vascular, enhancing mass in the pancreatic body clearly separate from the adrenal gland. Metaiodobenzylguanidine scan demonstrates focal intense uptake in the pancreatic body. The patient's diagnosis was confirmed with biopsy, and her malignancy responded well to conventional chemotherapy. The case is important in that it demonstrates the unusual imaging appearance of a primary

Full Text available with Trip Pro

2015 Radiology Case Reports

133. Psychiatric disorders, myoclonus dystonia and SGCE: an international study (PubMed)

Psychiatric disorders, myoclonus dystonia and SGCE: an international study Myoclonus-dystonia (M-D) is a hyperkinetic movement disorder, typically alcohol-responsive upper body myoclonus and dystonia. The majority of autosomal dominant familial cases are caused by epsilon-sarcoglycan gene (SGCE) mutations. Previous publications have observed increased rates of psychiatric disorders amongst SGCE mutation-positive populations. We analyzed the psychiatric data from four international centers

Full Text available with Trip Pro

2015 Annals of clinical and translational neurology

134. Clozapine-induced myoclonus: a case report and review of the literature (PubMed)

Clozapine-induced myoclonus: a case report and review of the literature We describe the case of a young man with treatment-resistant schizophrenia, who developed myoclonus during clozapine titration. This subsequently led to a full tonic-clonic seizure. Clozapine treatment can result in a range of seizure-like activity, the most well-known being tonic-clonic seizures. This case highlights the importance of recognizing and treating clozapine-induced myoclonus, as it can herald the onset (...) of a full seizure, even at low serum clozapine levels. We highlight the variety of ways myoclonus can present clinically and suggest treatment options.

Full Text available with Trip Pro

2015 Therapeutic Advances in Psychopharmacology

135. A case of alcoholic pellagra encephalopathy presenting with spinal myoclonus (PubMed)

A case of alcoholic pellagra encephalopathy presenting with spinal myoclonus 29595842 2019 02 26 2163-0402 5 6 2015 Dec Neurology. Clinical practice Neurol Clin Pract A case of alcoholic pellagra encephalopathy presenting with spinal myoclonus. 472-474 10.1212/CPJ.0000000000000165 Park Kwiyoung K Department of Neurology and Clinical Research Center, Utano National Hospital, Kyoto, Japan. Oeda Tomoko T Department of Neurology and Clinical Research Center, Utano National Hospital, Kyoto, Japan

Full Text available with Trip Pro

2015 Neurology: Clinical Practice

136. Alcohol-responsive Action Myoclonus of the Leg in Prostate Cancer: A Novel Paraneoplastic Syndrome? (PubMed)

Alcohol-responsive Action Myoclonus of the Leg in Prostate Cancer: A Novel Paraneoplastic Syndrome? Paraneoplastic movement disorders in prostate cancer are rare, and to our knowledge paraneoplastic myoclonus has not previously been reported.We report two men with adenocarcinoma of the prostate who developed isolated alcohol-responsive action myoclonus of one leg. Myoclonus was absent at rest but triggered by movement, standing, or walking. Evaluations excluded malignant invasion of the nervous (...) system, and testing for commercial paraneoplastic antibodies in serum and cerebrospinal fluid were unrevealing. Both patients experienced significant improvement with alcohol, and sodium oxybate was used in one patient with good initial benefit.Alcohol-responsive leg myoclonus might be a novel paraneoplastic syndrome associated with prostate cancer. The nature of the syndrome and the source of the myoclonus are currently unknown.

Full Text available with Trip Pro

2015 Tremor and Other Hyperkinetic Movements

137. Deterioration of palatal myoclonus after acute thalamic hemorrhage (PubMed)

Deterioration of palatal myoclonus after acute thalamic hemorrhage Palatal myoclonus (PM) is the hallmark of hypertrophic olivary degeneration (HOD); however, little is known regarding the association of thalamic lesions and PM. Case presentation: Here, we report a case of deteriorative PM after an acute small ventrolateral thalamic hemorrhage in a female Chinese patient with HOD. The sudden and severe deterioration of PM was preceded by at least 10 days of an occasionally occurring PM, which

Full Text available with Trip Pro

2015 Translational neuroscience

138. Familial segmental spinal myoclonus: a rare clinical feature of Friedreich’s ataxia (PubMed)

Familial segmental spinal myoclonus: a rare clinical feature of Friedreich’s ataxia Friedreich's ataxia (FRDA) is the most common autosomal recessive inherited ataxia. It is characterized by onset before the age of 25 year, progressive limb and truncal ataxia, lower limb areflexia, extensor plantars, dysarthria and impaired posterior column sensations. Other important associated features are skeletal deformity, hypertrophic cardiomyopathy and diabetes mellitus. Most of the patients (98%) have (...) an unstable homozygous trinucleotide (GAA) expansion in intron-1 of chromosome 9 and 2% patients are compound heterozygous for GAA expansion and point mutations.We observed an adolescence onset FRDA exhibiting spinal segmental myoclonus (SSM) in a family. Triplet repeat primed polymerase chain reaction (TP-PCR) demonstrated unstable expansion of >66 GAA repeats.SSM is a unique and rare manifestation of FRDA. This might be the first case report of SSM in FRDA patient.

Full Text available with Trip Pro

2015 SpringerPlus

139. An atypical form of AOA2 with myoclonus associated with mutations in SETX and AFG3L2. (PubMed)

An atypical form of AOA2 with myoclonus associated with mutations in SETX and AFG3L2. Hereditary ataxias are a heterogeneous group of neurodegenerative disorders, where exome sequencing may become an important diagnostic tool to solve clinically or genetically complex cases.We describe an Italian family in which three sisters were affected by ataxia with postural/intentional myoclonus and involuntary movements at onset, which persisted during the disease. Oculomotor apraxia was absent. Clinical (...) . Pathogenicity prediction and a yeast-functional assay suggested p.Gly116Arg impaired m-AAA (ATPases associated with various cellular activities) complex function.Exome sequencing is a powerful tool in identifying disease genes. We identified an atypical form of Ataxia with Oculoapraxia type 2 (AOA2) with myoclonus at onset associated with the c.6292C > T (p.Arg2098*) homozygous mutation. Because the same genotype was described in six cases from a Tunisian family with a typical AOA2 without myoclonus, we

Full Text available with Trip Pro

2015 BMC Medical Genetics

140. RELN rare variants in myoclonus-dystonia. (PubMed)

RELN rare variants in myoclonus-dystonia. Myoclonus-dystonia (M-D) is a hyperkinetic movement disorder with predominant myoclonic symptoms combined with dystonia of the upper part of the body. A proportion of M-D cases are caused by mutations in the epsilon-sarcoglycan gene. In remaining M-D patients, no genetic factor has been established, indicating genetic heterogeneity.Patients were included in a prospective clinical database and recruited from referral centers and general neurology clinics

2015 Movement Disorders

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>